Alexander I. Spira, MD, PhD

Panelists discuss how novel agents and emerging strategies may further optimize sequencing and outcomes for EGFR PACC-mutated NSCLC.

Panelists discuss how the FURTHER trial demonstrated firmonertinib’s efficacy and safety in patients with PACC mutations.

Panelists discuss how firmonertinib shows promise as a next-generation TKI with broad EGFR activity and favorable tolerability.

Panelists discuss how current TKI therapies offer limited efficacy for PACC mutations, necessitating individualized and trial-based approaches.

Panelists discuss how advanced genomic profiling techniques are vital for accurate detection of PACC mutations.

Panelists discuss how classifying EGFR mutations into molecular subgroups, including PACC, refines diagnosis and informs targeted treatment decisions.

Alexander I. Spira, MD, PhD, shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma.